214 results
8-K
LCTX
Lineage Cell Therapeutics Inc
28 May 14
BioTime’s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings
12:00am
litigation in the United States District Court for the Northern District of California (Civil Action No. C12-04813) seeking the reversal of two adverse … not include endoderm cell products, the costs and uncertain outcomes associated with continued litigation, and the opportunity to better focus its resources
DFAN14A
LCTX
Lineage Cell Therapeutics Inc
7 Jan 13
Additional proxy materials by non-management
12:00am
contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors … by BioTime and BAC with the SEC, and the other negotiated closing conditions; (iii) the possibility of litigation (including related to the transaction
8-K
EX-99.1
6avsggooob 98y
28 May 14
BioTime’s Subsidiary Asterias Biotherapeutics, Inc. Settles Patent Interference Proceedings
12:00am
8-K
EX-99.1
u6ndjour99vizqt8ne8
12 May 22
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm